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Renal involvement in Waldenström’s macroglobulinaemia
(WM) is very unusual when compared to multiple
myeloma. We report a case of a patient who developed
anuric acute kidney injury secondary to cast
nephropathy, dependent on high-ﬂux haemodialysis.
Complementary study revealed the presence of blood
IgM monoclonal gammopathy and a massive bone
marrow lymphoplasmacytic inﬁltration. There were no
osteolytic lesions and no clinical signs/symptoms of
hyperviscosity syndrome. The diagnosis of WM was
established and a dexamethasone plus
cyclophosphamide regime was started, in addition to
plasmapheresis. The patient partially recovered renal
function allowing haemodialysis and plasmapheresis
withdrawal. He remained asymptomatic with a good
response to chemotherapy and 12 months after his renal
function remained stable. This is a rare clinical case in
which WM presented as an IgM cast nephropathy,
which in turn is an extremely rare renal presentation of
this equally rare haematological disorder.
BACKGROUND
Waldenström’s macroglobulinaemia (WM) is a rare,
low-grade malignant lymphoplasmacytic prolifera-
tive disorder accounting for <5% of all
non-Hodgkin lymphomas and for approximately
2% of all haematological malignancies.1 2 It is a
distinct clinicopathological entity characterised by
bone marrow (BM) inﬁltration of a lymphoplasma-
cytic lymphoma (LPL), responsible for immuno-
globulin M (IgM) monoclonal gammopathy in the
blood.2 Other organs can be inﬁltrated, especially
liver and spleen. Renal involvement in WM is
unusual when compared to multiple myeloma
(MM) and results in monoclonal IgM deposition in
the glomerular basement membrane (GBM)
(±cryoglobulinaemia), interstitial inﬁltration of
neoplastic lymphoplasmacytic cells and/or amyloid
light-chain (AL)-amyloidosis typically causing neph-
rotic syndrome.3 Cast nephropathy can be seen
more frequently in MM (commonly referred to as
‘myeloma kidney’, a myeloma-deﬁning event) and
is otherwise extremely rare in WM.3 4 We report a
case of WM where cast nephropathy with acute
kidney injury (AKI) was not only its renal manifest-
ation but also its initial presentation.
CASE PRESENTATION
An 80-year-old Caucasian man was referred to our
nephrology department after a 24 h history of
anuric AKI. Concurrently, he presented with an
acute respiratory infection and was treated with
antibiotics, bronchodilators and oxygen.
The patient’s medical history was notable for dia-
betes mellitus (for 20 years, without evidence of
diabetic retinopathy), arterial hypertension, glau-
coma and asymptomatic cholelithiasis. There was
no known renal disease and his last known serum
creatinine, 3 years earlier, was 1.1 mg/dL. His out-
patient medication was composed exclusively of
metformin, glibenclamide, enalapril, clopidogrel
and ophthalmic drops.
On admission, he was afebrile with a blood pres-
sure of 139/56 mm Hg, bilateral pulmonary ronchi
but no respiratory distress. Cardiac and abdominal
examinations were unremarkable and there were
no cutaneous lesions, peripheral oedema or
adenopathies.
Initial laboratory studies yielded the following: nor-
mocytic and normochromic anaemia (Hb=9.3 g/dL)
with normal leucocyte and platelet blood count, ele-
vated C reactive protein (6.48 mg/dL, normal range
(NR) <0.5 mg/dL), serum creatinine 7.91 mg/dL,
blood urea nitrogen 89 mg/dL, hyperkalaemia
5.8 mmol/L, hyperglycaemia 263 mg/dL with border-
line hyponatraemia of 135 mmol/L and non-
compensated metabolic acidosis (pH=7.22, bicarbon-
ate 15.1 mmol/L, carbon dioxide pressure
37 mmHg, oxygen pressure 69 mmHg and normal
serum lactate). Chest X-ray was negative for pneu-
monic foci or pleural effusions. Renal ultrasound
revealed normal kidneys with no signs of obstruction
or nephrolithiasis.
During the ﬁrst few hours, the patient remained
anuric and was started on high-ﬂux haemodialysis.
Additional and relevant studies included: total
protein/albumin of 7.3/2.9 g/dL, normal lactic acid
dehydrogenase, corrected calcium 9.2 mg/dL,
hyperphosphoremia of 5.3 mg/dL and parathor-
mone of 120 pg/mL (NR 9–72 pg/mL). Glycated
haemoglobin was 6%, uric acid 3.9 mg/dL (NR
3.5–7.2 mg/dL) and folic acid 3.6 ng/mL (NR
>5.4 ng/mL). The levels of rheumatoid factor,
complement C3 and C4 and anti-streptolysin O
titre were normal. Antinuclear antibodies were also
normal and cryoglobulins were absent. Viral serolo-
gies were negative for hepatitis B surface antigen,
hepatitis C antibody, HIV 1 and 2 antibodies,
Epstein-Barr virus, cytomegalovirus and herpes
simplex virus. Peripheral blood cultures were
sterile. Serum electrophoresis revealed a monoclo-
nal spike in the β region, which was identiﬁed by
immunoelectrophoresis and immunoﬁxation as an
IgM M component bearing κ light chains: IgM
35.40 g/L (NR 0.40–2.30 g/L), κ light chains
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16.78 g/L (NR 6.66–14.65 g/L), κ/λ relation 3.94 (NR 1.35–
2.65), IgG 6.56 g/L (NR 7.0–16.0 g/L), IgA 0.65 g/L (NR 0.70–
4.00 g/L) and IgE 24 UI/mL (NR 0–100 UI/mL). Serum viscosity
was not performed, as signs/symptoms of hyperviscosity were
absent. Serum β2-microglobulin was 16.70 mg/L (NR 1.09–
2.53 mg/L).
Urine sediment (when the patient recovered urine output)
contained many erythrocytes, leucocytes and pathological cylin-
ders. Urine microbiological examination was negative.
Proteinuria was 4058 mg/g. Urine immunoelectrophoresis
revealed albumin and κ light chains (0.98 g/1 L urine/24 h).
BM aspirate revealed 75% of lymphoplasmacytic cells with
7% of plasmocytes and BM biopsy showed a massive inﬁltration
(90%) by lymphoplasmacytic cells. Flow cytometry demon-
strated 35% of IgM and κ light chain clonal B cells with the fol-
lowing immunophenotype: CD19+, CD20+, CD79b+,
CD38+ (heterogeneous expression), IgM and κ light chains,
CD10−, CD5− and CD23−. This immunophenotype was com-
patible with LPL/WM and no chromosomal abnormalities were
explored. Skeletal X-ray was negative for osteolytic lesions, and
a CT scan revealed multiple thoracic and abdominal lymphade-
nopathies without hepatosplenomegaly.
During the ﬁrst week, the patient remained dependent on
haemodialysis and a renal biopsy was performed (ﬁgures 1–6).
Light microscopy showed mild thickening of the capillary wall
and a slight mesangial expansion, PAS positive, without hyper-
cellularity. Double contoured basement membranes were absent.
There was mild interstitial ﬁbrosis, signs of ischaemic tubulopa-
thy and mild multifocal tubulointerstitial nephritis. Many renal
tubules showed PAS-positive casts, which became polychromatic
on Masson’s Trichrome stain. Immunohistochemical stain
revealed IgM deposits along the GBM and mesangium. Tubular
casts and peritubular capillaries also stained intensively for IgM
and moderately for κ light chains. Congo red and Wright stain-
ing were negative. Immunoﬂuorescence study revealed a strong
staining of casts and glomeruli for IgM, at this level granular,
mesangial and subepithelial. Electron microscopy was not
performed.
The patient was diagnosed with an AKI secondary to cast
nephropathy due to WM and was started on intravenous cyclo-
phosphamide 750 mg/m2 every 21 days, plus oral dexamethasone
10 mg twice a week. Also, plasmapheresis guided by serum para-
protein levels was performed on alternate days (therapeutic
plasma exchange using a centrifuge, with an exchange of
1.0 plasma volume and using 5% human albumin plus fresh-
frozen plasma as replacement ﬂuids) as well as MESNA protocol
and antibiotic prophylaxis. During hospitalisation, the patient was
Figure 1 Glomeruli with mild thickening of the capillary wall and
ischaemic tubulopathy with nuclei loss and cytoplasm vacuolisation
(asterisk). There are also intratubular casts (arrow) and tubulointerstitial
nephritis (star) (H&E, ×100).
Figure 3 Polychromatic intratubular casts (arrow) (Masson’s
Trichrome, ×400).
Figure 2 Periodic acid-Schiff (PAS)-positive casts (arrows) surrounded
by reactive epithelial cells and some mononucleated cells (PAS, ×200).
Figure 4 Casts with IgM intense expression by immunohistochemistry
(arrow). IgM is also expressed in peritubular capillaries lumina and in
the glomeruli (stars) (IgM, ×200).
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started on insulin therapy and submitted to 14 plasmapheresis
treatments plus three cycles of chemotherapy. There was a signiﬁ-
cant reduction in serum IgM and κ light chains to 7.74 and
5.56 g/L, respectively. The patient’s renal function slowly recov-
ered, becoming independent of haemodialysis, with a stable serum
creatinine of 4.5 mg/dL. His hospital admission was otherwise
uneventful and he was discharged after 56 days, dialysis free. He
was maintained on regular surveillance and a year later remained
asymptomatic with a serum creatinine of 2.68 mg/dL, a bland
urine sediment and proteinuria of 463 mg/g.
DISCUSSION
Our patient presented with a serum IgM monoclonal gammopa-
thy and an AKI secondary to a myeloma-like cast nephropathy,
with unusual and strong staining for IgM in addition to κ light
chains. In this case, and in general, the differential diagnosis
between rare diseases such as WM and classical MM with an
IgM paraprotein (IgM-MM) is challenging. The distinction is
made on clinical and cellular grounds. Classical MM is asso-
ciated with lytic bone lesions and AKI. Symptoms of hypervisc-
osity, the presence of lymphadenopathy and/or splenomegaly,
and the absence of osteolytic lesions support the diagnosis of
WM. Moreover, lymphoplasmacytic cells in the BM of patients
with WM are immunophenotypically different from plasma
cells seen in the BM of patients with MM. The clonal popula-
tion in WM appears to derive from a B-cell arrest before ter-
minal differentiation to a plasma cell and a surface IgM-positive
CD5−CD10−CD19+CD20+CD23− immunophenotype in
association with an intra-trabecular monoclonal lymphoplasma-
cytic inﬁltrate is diagnostic of WM.2 Cytogenetic studies are
optional in the diagnostic approach of a suspected case of WM
but sometimes helpful in patients with MM who may have lym-
phoplasmacytic or small mature plasma cell morphology, also
expressing CD20. In these cases, cytogenetic analysis to search
for t(11;14) chromosomal translocation may help establishing
the diagnosis, and its presence is in favour of an IgM-MM as
WM is not associated with speciﬁc chromosomal abnormalities.
In the present case, there was no cytogenetic analysis as the
clonal population had a characteristic immunophenotype that,
along with the clinical criteria, led to the diagnosis of WM.
According to the literature, there are few case reports describ-
ing patients with WM with cast nephropathy.5–8 Ours was
unique in two ways: (1) AKI was the clinical manifestation that
led to the diagnosis of WM, which is in itself a rare event in
WM and (2) renal biopsy documented the presence of cast
nephropathy with tubular casts expressing IgM and κ light
chains on immunohistochemical staining, which is also very
unusual in WM.
It is widely known that light-chain cast nephropathy, com-
monly referred to as myeloma cast nephropathy or myeloma
kidney, is the most common cause of AKI in MM, and is
related to a high tumoural burden.9 In MM, monoclonal free
light chains (FLC) are easily ﬁltered through the glomerular
ﬁltration barrier (Bence-Jones proteinuria). However, the high
FLC concentration overwhelms proximal tubule reabsorption
capacity, allowing for large amounts of FLC to reach the loop
of Henle, where Tamm-Horsfall protein (THP) is produced.
Here, they form obstructing tubular casts, which are the
result of FLC’s binding and aggregation to THP.4 The tubulo-
pathic FLC typically incite accompanying tubulointerstitial
nephritis.
Urinary monoclonal light chains can be detected by immuno-
ﬁxation in 80–90% of patients with WM, but signiﬁcant
Bence-Jones proteinuria (>1,0 g/day) only occurs in a small
fraction of those patients (<5%).3 9 This may help to explain
why cast nephropathy (and AKI) is so rare in WM.
Possible pathological patterns of renal involvement in WM
are: (1) glomerular lesions and (2) tubulointerstitial lesions. The
ﬁrst, which are most frequently encountered, consist of intraca-
pillary monoclonal deposit disease (intraglomerular periodic
acid-Schiff (PAS)-positive hyaline pseudothrombi occluding the
capillary lumens corresponding to monoclonal IgM aggregates),
membranoproliferative glomerulonephritis (±cryoglobulinae-
mia), light chain amyloidosis, light-chain deposition disease
(LCDD) and minimal change disease. The second are related to
lymphomatous inﬁltrate, acute tubular necrosis, cast nephropa-
thy, Fanconi syndrome and, also, LCDD.9–11
In our patient, glomerular and tubulointerstitial compart-
ments were both affected. Immunohistochemical stain and
immunoﬂuorescence pattern may suggest a deposit disease.
However, a deﬁnite diagnosis is not possible, as electronic
microscopy was not performed. Had it been conﬁrmed, there
would be a combination of cast nephropathy and deposit
disease, an even rarer histopathology in WM.11 But it is import-
ant to stress that patients’ staining patterns may represent non-
speciﬁc ‘trapping’ of the circulating M component in basement
membrane, which might be a reﬂection of high serum levels as
opposed to real deposits.11
Figure 5 The κ light chain immunohistochemical expression in the
casts, some of them showing lamination (arrow). (κ light chain, ×400).
Figure 6 IgM 3+ deposits in casts (arrows) (IgM
immunoﬂuorescence, ×400).
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It was also very interesting to ﬁnd IgM staining in tubular
casts. At ﬁrst sight, this might be difﬁcult to understand due to
its pentameric form and high molecular mass.12 However, IgM
has important physiochemical properties, such as aggregability,
polymerisation and cryoprecipitation, which may predispose to
its GBM trapping particularly where protein concentration is
especially elevated by glomerular ultraﬁltration. It may
somehow induce glomerular damage (without triggering glom-
erular proliferation) and non-selective proteinuria, explaining
the occurrence of IgM in tubular casts and, ultimately,
AKI.3 9 13
Another relevant issue in our patient’s renal dysfunction was
his long history of type 2 diabetes mellitus. However, renal
histopathology excluded co-existent diabetic nephropathy,
which could otherwise justify his residual renal dysfunction
after cast nephropathy treatment.
WM’s immunosuppressive treatment is the same as for MM,
and includes alkylating agents, purine analogues and monoclo-
nal antibody anti-CD20 (rituximab). The latter may be regarded
as a reasonable option in patients with IgM autoantibody-
related neuropathies (anti-myelin-associated glycoprotein anti-
bodies), which were absent in our patient.2 Moreover, plasma-
pheresis is indicated for the acute management of symptoms of
hyperviscosity (generally present when IgM>50 g/L), and, in
cast nephropathy, as an adjunct to chemotherapy, as it helps
remove the toxic circulating paraproteins (while their
production is being impaired by chemotherapy). However, there
are conﬂicting data regarding its effectiveness in patients with
AKI secondary to cast nephropathy.14–16
Despite having cast nephropathy, renal prognosis in this
patient with WM was better than for most patients with MM
with similar renal involvement. Even so, median survival of
patients with WM, from the time of diagnosis, is approximately
5 years and the majority die of disease progression (eg, trans-
formation to large cell lymphoma). The remaining succumb to
unrelated causes, as they are generally elderly.1 2
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Learning points
▸ Compared to multiple myeloma (MM), renal involvement in
Waldenström’s macroglobulinaemia (WM) is very unusual,
with glomerular lesions being the most frequently observed
abnormality.
▸ Cast nephropathy is extremely rare in WM since signiﬁcant
Bence-Jones proteinuria occurs in <5% of these patients.
▸ In rare cases, IgM trapping in glomerular basement
membrane may induce glomerular damage with the
appearance of IgM in tubular casts.
▸ WM treatment is the same as that for MM.
▸ Management of cast nephropathy with acute kidney injury
includes chemotherapy with or without plasmapheresis,
according to the current literature.
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